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Dr Raphael Bueno (Boston, Mass). Thank you for this elegant
presentation and elegant work. It is always nicer when the drug
that you discovered to have an effect in your cell line is approved
by the Food and Drug Administration and any physician can jus-
tify giving it. So the question for you is, what is your next step?
Are you going to add it to your postoperative regimen for patients
or are you going to do something else to look into it? If this im-
proves survival, why shouldn’t I start giving this drug to every-
body who has T3 N1 disease after resection for esophageal
cancer?
Dr Sadaria. That is an excellent question. The effects of sim-
vastatin have been investigated in various other cancers, but in
terms of esophageal adenocarcinoma, it has been researched
only in vitro. I think the next step for us is to look at it in vivo,
as you suggested, but probably in an animal model first to verify
the doses used and to ensure no adverse effects at these doses.
Depending on the results in an animal model, hoping, again, that
it will inhibit tumor metastases without significant side effects,
we will then plan to take it to the clinical level.
Dr FrankW. Sellke (Providence, RI).Did you look at other cell
surface adhesion molecules to see whether they had similar
effects?
Dr Sadaria. No, we have not evaluated other cell surface adhe-
sion molecules. Thus far in our laboratory, we have only looked at
the expression of ICAM-1. Now that we have demonstrated how
ICAM-1 expression is attenuated with simvastatin therapy, one
of the future directions we can take with this project is to look at
other cell surface adhesion molecules and observe how they may
be affected by statin therapy.
Dr Sellke. Why did you pick ICAM-1?
Dr Sadaria. ICAM-1 has actually been documented quite a bit
as a strong contributor to the tumor’s metastatic potential, more so
in other tumor cell lines than in esophageal cancer. We recently
published an article in regard to ICAM-1 and the metastatic poten-
tial of esophageal adenocarcinoma tumor cells. But again, we
based our choice of ICAM-1 on the fact that it has been widely
documented in other tumor cell lines as being an important con-
tributor in the tumor’s metastatic potential.gery c November 2011
